Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 6/20 | 0.82 |
| ▸ | NR2C2 | P49116 | 4/20 | 0.82 |
| ▸ | HCK | P08631 | 4/20 | 0.82 |
| ▸ | GCK | P35557 | 1/20 | 0.82 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.78 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | RAD52 | P43351 | 1/20 | 0.64 |
| ▸ | ATM | Q13315 | 1/20 | 0.64 |
| ▸ | CSF1R | P07333 | 4/20 | 0.63 |
| ▸ | KIT | P10721 | 4/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19928677 | 0.90 | EPHA2 (0.81) | BTKNR2C2HCKGCKEPHA2 | |
| SCHEMBL16810246 | 0.90 | BTK (1.00) | BTKNR2C2HCKGCKEPHA2 | |
| SCHEMBL29435037 | 0.87 | EPHA2 (1.00) | BTKNR2C2HCKGCKEPHA2 | |
| SCHEMBL20136698 | 0.87 | EPHA2 (1.00) | BTKNR2C2HCKGCKEPHA2 | |
| SCHEMBL29496427 | 0.87 | EPHA2 (1.00) | BTKNR2C2HCKGCKEPHA2 | |
| SCHEMBL18177735 | 0.86 | BTK (1.00) | BTKNR2C2HCKGCKEPHA2 | |
| SCHEMBL18177734 | 0.85 | BTK (1.00) | BTKNR2C2HCKGCKEPHA2 | |
| SCHEMBL18170278 | 0.84 | BTK (0.88) | BTKNR2C2HCKGCKEPHA2 | |
| SCHEMBL16810176 | 0.83 | BTK (1.00) | BTKNR2C2HCKGCKEPHA2 | |
| SCHEMBL20355914 | 0.82 | EPHA2 (0.95) | BTKNR2C2HCKGCKEPHA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9908872-B2 | Methods to treat lymphoplasmacytic lymphoma | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-03-06 | — | — | US | disclosed |